For example, vitiligo patients have melanocyte‐specific CD8+ T cells that are capable of killing melanocytes (van den Boorn et al., 2009; Ongenae, Van Geel, & Naeyaert, 2003; Palermo et al., 2001) and initiating antibody responses against melanocyte antigens, such as tyrosinase and TRP‐2 (Kemp, Gavalas, Gawkrodger, & Weetman, 2007). The gene discussed is CD8A; the disease is vitiligo.